AbbVie Commits $380M to Two AI-Enabled API Manufacturing Facilities in North Chicago
AbbVie will invest $380M to build two new API manufacturing facilities at its North Chicago campus, starting construction in spring 2026 and targeting full operation by 2029. The expansion includes advanced AI-integrated production capacity for next-generation neuroscience and obesity drugs and will create about 300 jobs locally.
1. Investment Details
AbbVie announced a $380M investment to construct two new active pharmaceutical ingredient manufacturing facilities located at its existing North Chicago campus. The facilities will integrate advanced manufacturing technologies, including AI-driven processes, to support production of next-generation neuroscience and obesity medications.
2. Construction Timeline
Construction is scheduled to begin in spring 2026, with both facilities expected to reach full operational status by 2029. This timeline aligns with AbbVie’s broader goal of enhancing domestic manufacturing capacity over the next decade.
3. Job Creation Impact
The project will create approximately 300 new positions, encompassing engineers, scientists, manufacturing operators and lab technicians. These roles will bolster AbbVie’s local workforce and support expanded production capabilities.
4. Strategic Significance
The North Chicago expansion is part of AbbVie’s $100B commitment to U.S. research, development and capital investments. By onshoring API production, the company aims to secure supply chains, reduce dependency on overseas facilities and reinforce its manufacturing footprint for future drug launches.